ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Value of 2 risk prediction models in predicting the risk of atherosclerosis in patients with chronic kidney disease.
Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesCardiovascular disease (CVD) remains a high morbidity in patients with chronic kidney disease (CKD), and atherosclerosis (AS) is the main pathological basis of CVD. Atherosclerotic cardiovascular disease (ASCVD) is one of the major complications and causes of death in CKD patients. Monitoring and paying attention to the risk of AS is the manifestation of multidisciplinary comprehensive treatment. Through continuous monitoring the risk factors of AS, patients with high AS risk can be detected early, and then risk factors can be treated to improve the prognosis and life quality of CKD patients and reduce the CVD mortality of CKD. The Framingham risk prediction model and Chinese 10-year ASCVD risk prediction model can comprehensively evaluate the AS risk. The predictive value of the 2 risk prediction models has been widely confirmed in the general population, but the application in CKD population needs to be further explored. Thus, the aim of this study is to analyze the value of the 2 risk prediction models in predicting AS risk of CKD population and to find a simple and reliable method to predict AS risk of CKD population.
methodsThis study was a cross-sectional study and 146 CKD patients (CKD group) and 14 healthy controls (control group) were recruited. Carotid ultrasound examination was performed to measure the intima-media thickness of left and right carotid arteries to evaluate the prevalence of AS. Medical history, physical examination, and clinical laboratory test data were collected to calculate Framingham Risk Score (FRS) and ASCVD score for all participants. We compared baseline data and AS positive rate between the CKD group and the control group. The AS positive rates detected by FRS, ASCVD score, and carotid ultrasound examination were compared in terms of Kappa consistency test, authenticity, reliability, and benefits.
resultsThere were no significant differences in sex, age, and BMI between the CKD group and the control group (all
conclusionsThe positive rates of AS in CKD patients detected by risk prediction models are not different from that detected by carotid artery ultrasound, and there are good consistency and coincidence rate among risk prediction models and carotid artery ultrasound. Risk prediction models are suitable for predicting the risk of AS in patients with CKD, and the combined application of them can further improve the sensitivity or specificity of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.